Exporter

Codes ATC: J01DD04
Indication
Inflammatory and other diseases of prostate Code ICD11: GA91.Z
INN
Ceftriaxone
Type de médicament
Chemical agent
Groupes d'antibiotiques
Type de liste
Liste de base
Additional notes
Do not administer with calcium and avoid in infants with hyperbilirubinaemia.
Formulations
Parenteral > General injections > unspecified: 2 g in vial powder for injection (as sodium salt) (EML) ; 500 mg in vial powder for injection (as sodium salt) ; 250 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt)
Historique des statuts LME
Ajouté pour la première fois en 2017 (TRS 1006)
Modifié en 2023 (TRS 1049)
Sexe
Mâle
Âge
Adolescents et adultes
Limite d'âge
> 41 weeks corrected gestational age
Équivalence thérapeutique
La recommandation concerne ce médicament spécifique
Renseignements sur le brevet
Patents have expired in most jurisdictions
Lire la suite sur les brevets.
Wikipédia
DrugBank
Recommandation du comité d'experts
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.
Recommandations de la LME : Inflammatory and other diseases of prostate
Premier choix
Second choix
mild to moderate
severe
Premier choix
ceftriaxone co-prescrite avec amikacin
cefotaxime co-prescrite avec amikacin
Second choix